<DOC>
	<DOCNO>NCT00533273</DOCNO>
	<brief_summary>This 12-month study two phase : 90-day double-blind , randomize , placebo-controlled phase nine-month open-label extension phase . Before treatment , eligible subject stratify primary joint type ( 30 metacarpophalangeal [ MP ] joint 30 proximal interphalangeal [ PIP ] joint ) severity primary joint contracture ( ie , 50° &gt; 50° MP joint 40° &gt; 40° PIP joint ) randomize 2:1 ratio either AA4500 0.58 mg placebo . Upon completion double-blind phase ( ie , 90-day evaluation first injection ) , subject eligible enter open-label extension phase study follow additional nine month . Subjects require treatment either achieve reduction contracture 5° less , cord affect primary joint receive placebo , another cord receive less three injection AA4500 , untreated cord affect joint option receive five additional injection AA4500 0.58 mg open-label extension phase , individual cord receive three injection AA4500 . This study design part large clinical program , adult patient Dupuytren 's contracture palpable cord , data 2 pivotal Placebo-Controlled study ( AUX-CC-857 [ NCT00528606 ] AUX-CC-859 [ NCT00533273 ] ) 7 non-pivotal study evaluate .</brief_summary>
	<brief_title>Non-US Study AA4500 ( XIAFLEX™ , Proposed Name ) Treatment Advanced Dupuytren 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>Subjects diagnosis advance Dupuytren 's disease , fix flexion deformity least one finger , thumb , contracture least 20° , great 100° , MP ( 80° PIP ) joint , cause palpable cord . Had positive `` table top test , '' define inability simultaneously place affect finger ( ) palm flat table top . Were naive AA4500 treatment Were judge good health , base upon result medical history , physical examination , safety laboratory profile . Had chronic muscular , neurological , neuromuscular disorder affect hand . Had receive treatment advance Dupuytren 's disease , include surgery ( fasciectomy surgical fasciotomy ) , needle aponeurotomy/fasciotomy , injection verapamil and/or interferon select primary joint within 90 day first dose study drug . Had know recent history stroke , bleeding , disease process affect hand , medical condition , investigator 's opinion , would make subject unsuitable enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>